Clinical trials: Heart Failure, Systolic
Heart Failure
The Effects of Sacubitril/Valsartan on Cardiac Oxygen Consumption and Efficiency of Cardiac Work in Heart Failure Patients
This is a phase IV, prospective, randomized, double-blind, double-dummy, parallel-group study. The study assessed the effects of 6 weeks of stable sacubitril/valsartan therapy, as compared with valsartan therapy, on the…
- Trial name
- TurkuPET (NCT03300427)
- Testing
- sacubitril/valsatran, valsartan
- Where
- Finland
- Volunteers
- 55 people
- Sponsor
- Novartis Pharmaceuticals
Heart Failure, Congestive, Myocardial Infarction
IMPROVE HF: Registry to Improve the Use of Evidence-Based Heart Failure Therapies in the Outpatient Setting
The purpose of this study is to characterize current management of patients with either heart failure or prior myocardial infarction and left ventricular dysfunction and to assess the effect of education, specific clinical…
- Conditions
- Heart Failure, Congestive, Myocardial Infarction, Ventricular Dysfunction, Left
- Trial name
- IMPROVE-HF (NCT00303979)
- Where
- 144 sites in United States
- Volunteers
- 34,810 people
- Sponsor
- Medtronic Cardiac Rhythm and Heart Failure
Congestive Heart Failure, Left Bundle Branch Block
MIRACLE EF Clinical Study
This study is looking at whether the electrical treatment provided by a special type of pacemaker called a Cardiac Resynchronization Therapy (CRT) pacemaker may keep a patient's heart failure from getting worse.
- Conditions
- Congestive Heart Failure, Left Bundle Branch Block, Systolic Heart Failure
- Trial name
- MIRACLE EF (NCT01735916)
- Testing
- CRT-P Implant, CRT-P OFF
- Where
- 73 sites in United States, India and 3 more
- Volunteers
- 44 people
- Sponsor
- Medtronic Cardiac Rhythm and Heart Failure
Heart Failure
Open-label Extension Study to Evaluate Long-term Safety of Sacubitril/Valsartan in Pediatric Patients With HF
The purpose of this study was to evaluate long-term safety and tolerability and to provide post-trial access to sacubitril/valsartan to eligible participants who successfully completed CLCZ696B2319 (PANORAMA-HF) core study Part 2…
- Trial name
- NCT03785405
- Testing
- sacubitril/valsartan
- Where
- 79 sites in United States, Argentina and 25 more
- Volunteers
- 216 people
- Sponsor
- Novartis Pharmaceuticals
Hypertension
Systolic Blood Pressure Intervention Trial
Elevated blood pressure (BP) is an important public health concern. It is highly prevalent, the prevalence may be increasing, and it is a risk factor for several adverse health outcomes, especially coronary heart disease, stroke…
- Trial name
- SPRINT (NCT01206062)
- Testing
- Intensive control of SBP, Standard control of SBP
- Where
- United States
- Volunteers
- 9,361 people, healthy volunteers welcome
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Heart Failure
A Safety Study of Sacubitril/Valsartan in Japanese Pediatric Patients With Heart Failure Due to Systemic Left Ventricle Systolic Dysfunction Who Have Completed CLCZ696B2319E1 Study
The purpose of this open-label study was to collect additional safety information of sacubitril/valsartan and to provide post-trial access to sacubitril/valsartan for the eligible Japanese patients who completed…
- Trial name
- NCT06149104
- Testing
- sacubitril/valsartan
- Where
- 6 sites in Japan
- Volunteers
- 8 people
- Sponsor
- Novartis Pharmaceuticals
Heart Failure, Sleep Disordered Breathing
Treatment of Predominant Central Sleep Apnoea by Adaptive Servo Ventilation in Patients With Heart Failure
The purpose of this trial is to evaluate the long-term effects and cost-effectiveness of adaptive servo-ventilation (ASV) on the mortality and morbidity of patients with stable heart failure due to left ventricular systolic…
- Trial name
- Serve-HF (NCT00733343)
- Testing
- Europe: AutoSet CS (USA: VPAP Adapt SV)
- Where
- 267 sites in Australia, Czechia and 9 more
- Volunteers
- 1,325 people
- Sponsor
- ResMed
Chronic Heart Failure With Reduced Systolic Function
Dapagliflozin Effect on Symptoms and Biomarkers in Patients With Heart Failure
The primary purpose of this study is to evaluate the impact of dapagliflozin, as compared with placebo, on heart failure disease-specific biomarkers, symptoms, health status, and quality of life in patients with chronic heart…
- Trial name
- DEFINE-HF (NCT02653482)
- Testing
- Dapagliflozin
- Where
- 25 sites in United States
- Volunteers
- 263 people
- Sponsor
- Saint Luke's Health System
Heart Failure, Systolic
Nicotinamide Riboside in Systolic Heart Failure
Mitochondrial dysfunction has been implicated in heart failure (HF), and is associated with an imbalance in intracellular ratio of reduced nicotinamide-adenine dinucleotide (NADH) to oxidized nicotinamide-adenine dinucleotide…
- Trial name
- NCT03423342
- Testing
- nicotinamide riboside
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- University of Washington
Heart Failure, Systolic, Diabetes Mellitus, Type 2
Treatment of Diabetes in Patients With Systolic Heart Failure
Investigator Initiated Study to study the effects of Canagliflozin 100 milligrams (mg) vs Sitagliptin 100 mg on parameters of aerobic exercise capacity (peak oxygen consumption [VO2]) and ventilator efficiency (minute ventilation…
- Trial name
- NCT02920918
- Testing
- Canagliflozin, Sitagliptin
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- Virginia Commonwealth University
Chronic Heart Failure
Effects of Ivabradine on Cardiovascular Events in Patients With Moderate to Severe Chronic Heart Failure and Left Ventricular Systolic Dysfunction. A Three-year International Multicentre Study
The primary objective of this study is to demonstrate the superiority of ivabradine over placebo in the reduction of cardiovascular mortality or hospitalisation for worsening heart failure in patients with moderate to severe…
- Trial name
- SHIFT (NCT02441218)
- Testing
- Ivabradine
- Where
- 2 sites in France, Sweden
- Volunteers
- 6,505 people
- Sponsor
- Institut de Recherches Internationales Servier
Heart Failure, Ventricular Dysfunction, Left
Evaluation of Heart Failure Treatment Guided by N-terminal Pro B-type Natriuretic Peptide (NTproBNP) vs Clinical Symptoms and Signs Alone
The purpose is to study if HF treatment guided by NTproBNP in addition to clinical symptoms and signs is more effective than treatment guided by clinical symptoms and signs alone in patients with HF and left ventricular systolic…
- Trial name
- NCT00391846
- Testing
- Captopril, Enalapril, Lisinopril
- Where
- 39 sites in Sweden
- Volunteers
- 252 people
- Sponsor
- AstraZeneca
Heart Failure, Systolic, Inflammation
Interleukin-1 Blockade In Recently Decompensated Heart Failure - 2
REDHART2 is a randomized, double-blinded, placebo-controlled trial to determine the effects of Anakinra on peak aerobic exercise capacity measured with a cardiopulmonary test after 24 weeks in patients with recently decompensated…
- Trial name
- REDHART2 (NCT03797001)
- Testing
- Anakinra
- Where
- United States
- Volunteers
- 102 people
- Sponsor
- Virginia Commonwealth University
Congestive Heart Failure
Louisiana State University Health Care Sciences Division (LSU HSCD) Tele-Health Projects: Adult CHF Patient Population
The purpose of this research study is to see whether a tele-health intervention can improve health, functioning status, emotional status, quality of life, and patient satisfaction for patients with Congestive Heart Failure (CHF)…
- Trial name
- TeleHealth:CHF (NCT01148563)
- Testing
- Tele-health Monitoring
- Where
- 4 sites in United States
- Volunteers
- 136 people
- Sponsor
- Pennington Biomedical Research Center
Non-ischemic Cardiomyopathy, Systolic Heart Failure (NYHA II-III)
Safety and Efficacy of Doxycycline in Patients With Non-Ischemic Cardiomyopathy
Non-ischemic cardiomyopathy and heart failure are highly influenced by the presence of systemic inflammation. Doxycycline is a FDA-approved drug to treat bacterial infections which also shows powerful anti-inflammatory effects.
- Trial name
- DOXY-HF (NCT01935622)
- Testing
- Doxycycline
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Virginia Commonwealth University
Chronic Heart Failure With Preserved Systolic Function
Dapagliflozin in PRESERVED Ejection Fraction Heart Failure
The primary purpose of this study is to evaluate the impact of dapagliflozin, as compared with placebo, on heart failure, disease specific biomarkers, symptoms, health status and quality of life in patients with chronic heart…
- Trial name
- PRESERVED-HF (NCT03030235)
- Testing
- Dapagliflozin 10Mg Oral Tablet
- Where
- 26 sites in United States
- Volunteers
- 324 people
- Sponsor
- Saint Luke's Health System
Heart Failure, Anemia
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
The purpose of the study is to determine the efficacy of treatment of anemia with darbepoetin alfa compared to placebo on the composite of time to death from any cause or first hospital admission for worsening heart failure in…
- Conditions
- Heart Failure, Anemia, Cardiovascular Disease, Ventricular Dysfunction
- Trial name
- NCT00358215
- Testing
- Darbepoetin alfa
- Where
- 754 sites in United States, Argentina and 34 more
- Volunteers
- 2,278 people
- Sponsor
- Amgen
Cardiovascular Diseases, Heart Diseases
Aldosterone Antagonist Therapy for Adults With Heart Failure and Preserved Systolic Function
The purpose of this study is to evaluate the effectiveness of aldosterone antagonist therapy in reducing cardiovascular mortality, aborted cardiac arrest, and heart failure hospitalization in patients who have heart failure with…
- Conditions
- Cardiovascular Diseases, Heart Diseases, Heart Failure, Congestive
- Trial name
- TOPCAT (NCT00094302)
- Testing
- Spironolactone
- Where
- 270 sites in United States, Argentina and 4 more
- Volunteers
- 3,445 people
- Sponsor
- Carelon Research
Heart Failure, Asymptomatic Systolic Dysfunction
Human B-type Natriuretic Peptide (BNP) (Nesiritide) to Help Heart, Kidney, and Hormonal Functions in Persons With Lower Heart Pumping Function
The following are done for screening procedures to determine if patients are eligible for this study: blood count, kidney and liver blood tests. Patients will complete a 6-minute walk test.
- Trial name
- NCT00405639
- Testing
- Nesiritide
- Where
- United States
- Volunteers
- 37 people, healthy volunteers welcome
- Sponsor
- Mayo Clinic
Heart Failure, Heart Failure Hospitalization
Teach-Back Discharge Education to Improve Self-Care and Reduce 30-Day Readmissions in Heart Failure Patients
This study aimed to improve how patients with heart failure understand and manage their condition after leaving the hospital. Many heart failure patients are readmitted within 30 days due to confusion about their discharge…
- Conditions
- Heart Failure, Heart Failure Hospitalization, Readmission, Hospital
- Trial name
- NCT07280208
- Testing
- Teach-Back Discharge Education
- Where
- United States
- Volunteers
- 57 people
- Sponsor
- Nova Southeastern University